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Abstract Vascular endothelial growth factor (VEGF) and its
receptors play a key role in angiogenesis. VEGF receptor-2
(VEGFR-2) has a tyrosine kinase domain, and, once activated,
induces the phosphorylation of cytoplasmic signaling proteins.
The phosphorylated VEGFR-2 may be a substrate for intracel-
lular protein tyrosine phosphatases (PTPs) which prevent
VEGF signaling. We synthesized a series of K,K-di£uoro(phe-
nyl)methylphosphonic acids (DFPMPAs) which inhibit the ac-
tion of PTP. In this study, we test their e¡ects on VEGF-in-
duced angiogenesis. DFPMPA-3, the most e¡ective inhibitor of
human PTP-1B, promoted tube formation by human umbilical
vein endothelial cells (HUVEC) on Matrigel more e¡ectively
than any other DFPMPAs. The inhibitor promoted the
VEGF-induced proliferation and migration of HUVEC by in-
hibiting the dephosphorylation of VEGFR-2. Its e¡ectiveness
was proven through neo-vascularization in mice. The present
¢ndings suggest that targeting PTP to promote therapeutic
neo-vascularization may be a potential strategy. 3 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Vascular endothelial growth factor (VEGF) is a potent se-
lective cytokine that acts on endothelial cells to promote the
sprouting of blood vessels [1,2]. The angiogenic action of
VEGF is mediated through VEGF receptor-2 (VEGFR-2)
and the downstream phosphatidylinositol 3P-kinase (PI-3K)/
Akt signaling pathway [3]. The binding of VEGF to VEGFR-
2 induces conformational changes in the receptor, followed by
dimerization and autophosphorylation of the tyrosine residues
[4,5]. Thereafter, consecutive intracellular signal transduction
events are initiated and culminate in VEGF-mediated angio-
genesis.
Recently, successful VEGF gene therapy to treat patients
with critical limb ischemia has been reported [6,7]. However,
in some cases, such direct administration of the VEGF gene
alone may not be su⁄cient to treat impaired neo-vasculariza-
tion. It is known that older, diabetic, and hypercholesterole-
mic animals exhibit evidence of age-related endothelial dys-
function [8^10]. We hypothesize that the cause of this
dysfunction is the presence of intracellular protein tyrosine
phosphatase(s) (PTP), which switches o¡ active VEGFR-2
through dephosphorylation of the tyrosine residues. Using a
small molecule to block the dephosphorylation and thereby
maintain the phosphorylated state of the tyrosine kinase do-
main would be useful as a ‘support-side’ strategy in neo-vas-
cularization via gene therapy.
We synthesized a series of K,K-di£uoro(phenyl)methylphos-
phonic acids (DFPMPAs) having a hydrophobic functional
group and evaluated their inhibitory e¡ects on human PTP-
1B [11]. For the present study, we chose six DFPMPA deriv-
atives with IC50 values varying from 57.94 to 718.1 WM [11].
We studied the e¡ectiveness of these small-molecule stimula-
tors on the angiogenic process by using a tube formation
assay on Matrigel. We found that DFPMPA-3, the most ef-
fective PTP-1B inhibitor with an IC50 = 57.94 WM, is capable
of enhancing VEGF-induced proliferation and migration of
human umbilical vein endothelial cells (HUVEC) by prolong-
ing the phosphorylated state of the kinase domain of
VEGFR-2. We also show the e⁄cacy of DFPMPA-3 on
neo-vascularization in mice.
2. Materials and methods
2.1. Materials
The following reagents were obtained commercially: Matrigel from
Becton Dickinson Labware; fetal bovine serum (FBS) and Dulbecco’s
modi¢ed Eagle’s medium (DMEM) from Gibco BRL; porcine type I
and type IV collagens from Nitta Gelatin, Osaka, Japan; human
plasma ¢bronectin from Boehringer; human plasminogen from Amer-
ican Diagnostica; recombinant human VEGF165 from Oncogene Re-
search Products; wortmannin from Sigma. A series of DFPMPAs
were prepared from 2-iodonaphthalene and iodobenzene derivatives
as described previously [11].
2.2. Cell cultures
Cryo HUVEC and the culture medium EGM-2 were purchased
from Sanko Junyaku, Tokyo, Japan. EGM-2 is composed of modi¢ed
MCDB 131 medium and supplements that contain FBS, VEGF, epi-
dermal growth factor, basic ¢broblast growth factor, insulin-like
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growth factor, heparin, ascorbic acid, hydrocortisone, amphotericin B
and gentamicin. HUVEC were grown in EGM-2 at 37‡C in a humidi-
¢ed 5% CO2 atmosphere. All experiments were performed with HU-
VEC at passages 3^5.
2.3. Tube formation assays
For the assay using Matrigel, diluted Matrigel (350 Wl) was placed
into each well of a 24-well culture plate at 4‡C and allowed to poly-
merize by incubation at 37‡C for 30 min. HUVEC (5U104 cells) were
seeded on the Matrigel in 1 ml of DMEM/2% FBS alone or with
DFPMPA, and incubation followed at 37‡C for 24 h. Three di¡erent
phase-contact microscopic ¢elds (U100) per well were photographed.
The total length of tube structures in each photograph was scanned
and quanti¢ed using NIH Imaging software. For the tube formation
assay using collagen gel, 350 Wl of a type I collagen solution (2.4 mg/
ml) containing VEGF (50 ng/ml), ¢bronectin and plasminogen (20 Wg/
ml each) was placed into each well of a 24-well culture plate at 4‡C
and polymerized at 37‡C for 30 min. The subsequent procedures were
the same as those described above for the assay using Matrigel.
2.4. Assay of cell proliferation
HUVEC (5U103 cells) in EGM-2 containing 100 Wl of VEGF (10
ng/ml) were seeded into each well of 96-well culture plates and incu-
bated at 37‡C for 24 h. Cell proliferation was assayed with a MTT
Cell Proliferation kit I (Roche Diagnostics), following the manufac-
turer’s instructions.
2.5. Assay of cell migration
HUVEC (1U103 cells) were seeded on type IV collagen-coated
Transwell chambers (Falcon), and the chamber was inserted into
each well of 24-well culture plates containing VEGF (50 ng/ml), ¢-
bronectin, plasminogen (20 Wg/ml each) and, where indicated,
DFPMPA-3 in a total volume of 700 Wl. After 24 h incubation, HU-
VEC remaining on the upper side of the membrane were removed
with cotton swabs. The cells were then ¢xed with a 5% glutaraldehyde
solution and stained with Giemsa’s reagent (Merck). The stained cells
were microscopically counted in three ¢elds (U100).
2.6. Western blot analysis of phosphorylated VEGFR-2
Con£uent cultures of HUVEC in 175-cm2 culture £asks were incu-
bated for 3 h in DMEM/0.05% FBS and further for 30 min in
DMEM/2% FBS that contained VEGF (10 ng/ml) and, where indi-
cated, DFPMPA-3. The cells were harvested and pelleted by centrifu-
gation. The pellets were washed with cold phosphate-bu¡ered saline,
and extraction followed for 10 min in 100 Wl of a lysis bu¡er, 10 mM
HEPES bu¡er (pH 7.5)/50 mM KCl/3 mM MgCl/0.3 mM EDTA/10%
glycerol/0.5% Nonidet P-40/leupeptin (10 Wg/ml)/antipain (10 Wg/ml).
After centrifugation at 12 000Ug for 15 min, the resulting superna-
tants were assayed to detect phosphorylated VEGFR-2. Supernatants
(30 Wg protein) were separated by 10% SDS^PAGE and transferred to
polyvinylidene di£uoride membrane. The transferred proteins were
reacted with antibodies against phospho-VEGFR-2 (Oncogene Re-
search Products). The resulting immune complex was further reacted
with peroxidase-conjugated secondary antibodies and made visible
with 4-chloro-1-naphthol as the peroxidase substrate.
2.7. Animal studies
Male ICR mice (5 weeks old) were purchased from Charles River
Japan, Kanagawa, Japan. Animal treatment followed the animal care
guidelines of the Japanese Government, Law No. 105 and Noti¢ca-
tion No. 6. Neo-vascularization in mice was assessed by the method of
Asano et al. [12]. Brie£y, diluted Matrigel alone or with DFPMPA-3
was packed into a di¡usion chamber (Millipore), and the chamber
was implanted into the dorsal air sac of mice. After 7 days, the blood
vessels newly formed in the subcutaneous regions adjacent to the
implanted chamber were photographed under a dissection micro-
scope.
2.8. Statistical analysis
All values are expressed as meanTS.D., and signi¢cant levels be-
tween groups were assessed by Student’s t-test.
Fig. 1. Characterization of DFPMPAs: chemical structures, IC50 values, and their e¡ects on tube formation by HUVEC on Matrigel. IC50 val-
ues are quoted from our previous paper [11]. The enzyme assay was performed with p-nitrophenyl phosphate as the substrate. The e¡ects of
DFPMPAs on tube formation were evaluated at a concentration of 10 WM. Each value represents the meanTS.D. (n=3). *P6 0.05;
**P6 0.01; ***P6 0.005, compared to the control. NI, no inhibition.
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3. Results and discussion
3.1. The e¡ect of DFPMPAs on HUVEC tube formation
Fig. 1A shows the chemical structure of DFPMPA. Fig. 1B
presents the structure of each DFPMPA derivative we used,
its IC50 values for human PTP-1B, and its e¡ect on HUVEC
tube formation. It has been reported that DFPMPA itself has
no inhibitory e¡ect on PTP-1B, but the naphthyl derivative,
DFPMPA-1, can bind to the catalytic site of PTP-1B and
competitively inhibit enzyme activity [11]. The inhibitory ef-
fect of DFPMPA-2, which has an (E)-styryl group on the
benzene nucleus, is superior to that of DFPMPA-1. The
most e¡ective derivative is DFPMPA-3, which contains a
bis-methylsulfonamide group. DFPMPAs 4 and 5 also con-
tain these groups, but are not as e¡ective as DFPMPA-3. The
data show that the e¡ectiveness of DFPMPAs in promoting
HUVEC tube formation corresponds in inhibiting PTP-1B.
The screening assay identi¢ed DFPMPA-3 as the most e¡ec-
tive stimulator of HUVEC tube formation. Okadaic acid, a
potent inhibitor of serine-threonine protein phosphatase [13],
had little or no e¡ect on HUVEC tube formation at a con-
centration of 10 WM (data not shown). This result suggests
that inhibition of PTP is an important factor in HUVEC tube
formation on Matrigel.
To determine whether the target of DFPMPAs is VEGFR-
related PTP, we examined the e¡ect of DFPMPA-3 on
VEGF-induced tube formation by HUVEC on type I collagen
gel (Fig. 2). Under experimental conditions, control HUVEC
failed to form the capillary-like networks (panel A). However,
as shown in panels B and C, DFPMPA-3 promoted the for-
mation of capillary-like networks by HUVEC. However, the
addition of 25 or 50 WM DFPMPA-3 did not cause additional
enhancement of the e¡ect. These results indicate that
DFPMPA-3 produces its best e¡ect on VEGF-induced tube
formation by HUVEC at a concentration of 10 WM and that
higher concentrations of the inhibitor may have some cyto-
toxic action on HUVEC, although cell death was not ob-
served.
3.2. The e¡ect of DFPMPA-3 on the VEGF-induced
proliferation, migration and receptor phosphorylation of
HUVEC
Neo-vascularization in adults has been thought to result
exclusively from proliferation, migration, and remodeling of
preexisting endothelial cells [14,15]. Because the most impor-
tant mediator in these processes is VEGF [1,2], we next tested
the e¡ect of DFPMPA-3 on VEGF-induced proliferation and
migration of HUVEC on type IV collagen gel. As shown in
Fig. 3A,B, DFPMPA-3 signi¢cantly promoted these VEGF-
induced angiogenic processes. DFPMPA-3’s best e¡ects were
obtained at a concentration of 10 WM (1.9-fold and 2.5-fold
increases, respectively, for cell proliferation and migration).
Tyrosine phosphorylations induced by receptor tyrosine ki-
nases promote cellular proliferative responses, and protein ty-
rosine phosphatases counterbalance the activities of tyrosine
kinase receptors [16]. Recent studies provide evidence that a
low molecular weight PTP exists in the cytoplasm of HUVEC
and prevents VEGF-induced cell migration, proliferation, and
the resulting angiogenesis [17]. An earlier report indicates that
the tyrosine kinase domain of VEGFR-2 is a substrate for the
cytoplasmic PTP [18]. Thus, DFPMPA-3 may increase the
amount of autophosphorylated VEGFR-2 by inhibiting the
cytoplasmic PTP present in HUVEC. Western blot analysis
using antibodies against phosphorylated VEGFR-2 demon-
strates that the phosphorylated protein migrating at V210
kDa during SDS^PAGE represents VEGFR-2, since VEGF
increased the phosphorylation of the protein to approximately
1.4 times that of the control (Fig. 4A,B). The presence of
10 WM DFPMPA-3 further increased the phosphorylated
VEGFR-2 levels, compared to VEGF alone (approximately
1.3 times the VEGF level, P6 0.005). These results suggest
that VEGF-mediated signaling in HUVEC is regulated by a
PTP, and that the inhibition of PTP activity can enhance the
Fig. 2. The e¡ect of DFPMPA-3 on VEGF-induced tube formation
by HUVEC on type I collagen gel. The photographs show results
from one of three experiments that produced very similar results.
Fig. 3. The e¡ect of DFPMPA-3 on VEGF-induced proliferation
(A) and migration (B) of HUVEC. Each bar represents the
meanTS.D. (proliferation, n=3; chemotaxis, n=6). *P6 0.05;
**P6 0.01; ***P6 0.005, compared to the control.
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VEGFR-2 signal transduction that leads to the proliferation,
migration and tube formation by HUVEC. However, it re-
mains to be determined whether the PTP activity is mediated
by the cytoplasmic PTP [17].
3.3. PI-3K is involved in DFPMPA-3’s enhancement of
VEGF-mediated angiogenic responses
PI-3K is known to a¡ect the ability of VEGF to enhance
the survival of HUVEC [3]. PI-3K is thought to resist cell
death by activating the serine-threonine protein kinase, Akt,
which enhances the activity of anti-apoptotic proteins through
the transcription factor NF-UB and inhibits pro-apoptotic sig-
naling by Bad, caspase-9, and other e¡ectors [19]. To assess
whether DFPMPA-3’s enhancement of VEGF-mediated an-
giogenic responses of HUVEC involves PI-3K signaling, we
used a speci¢c PI-3K inhibitor, wortmannin, in cell prolifer-
ation and migration assays of HUVEC. As shown in Fig. 5,
the PI-3K inhibitor (50 or 100 nM) diminished the ability of
DFPMPA-3 to promote VEGF-induced proliferation (panel
A) and migration (panel B). These results suggest that the
inhibition of dephosphorylation of VEGFR-2 by a PTP in-
hibitor, DFPMPA-3, contributes to ampli¢cation of the PI-
3K/Akt signaling that plays an important role in anti-apopto-
sis of endothelium [3,19] and ischemic neurons [20].
3.4. DFPMPA-3 promotes angiogenesis in mice
Since DFPMPA-3 promoted the VEGF-mediated signaling
and cellular responses in cultured HUVEC, we next studied
whether DFPMPA-3 was able to promote angiogenesis in
vivo. A di¡usion chamber containing diluted Matrigel (as
the chemoattractant) alone or with DFPMPA-3 was im-
planted into the dorsal air sac of mice. After 7 days, neo-
vascularization in the subcutaneous region adjacent to the
implanted chamber was observed under a dissection micro-
scope. The chamber containing Matrigel alone produced few
vascular sprouts (Fig. 6A). In contrast, the presence of
DFPMPA-3 in the chamber produced a luxuriant develop-
ment of vascular sprouts in a dose-dependent manner (Fig.
6B,C).
We conclude that DFPMPA-3 is a small-molecule stimula-
tor of VEGFR-2 signaling. A possible target molecule for
DFPMPA-3 may be the cytoplasmic PTP [17]. The potential
importance of therapeutic angiogenesis has been proved [21].
Successful therapeutic angiogenesis has been achieved by de-
Fig. 4. The e¡ect of DFPMPA-3 on VEGF-induced autophosphory-
lation of VEGFR-2. The phosphorylated VEGFR-2 was made visi-
ble by Western blotting (B), and the bands were quanti¢ed using an
NIH Imager (A). VEGFR-2 in HUVEC incubated in the absence of
both VEGF and DFPMPA-3 was used as the control. The data are
results from one of two experiments that produced very similar.
***P6 0.005, compared to VEGF alone.
Fig. 5. The e¡ect of wortmannin on the ability of DFPMPA-3 to
enhance VEGF-induced proliferation (A) and migration (B) of HU-
VEC. Each bar represents the meanTS.D. (proliferation, n=3; che-
motaxis, n=6). **P6 0.01; ***P6 0.005, compared to DFPMPA-3
alone.
Fig. 6. The e¡ect of DFPMPA-3 on angiogenesis in mice. Photo-
graphs show neo-vascularization induced by a chemoattractant, Ma-
trigel, alone (A) or with DFPMPA-3 (B,C) packed in the membrane
chamber.
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livery of the VEGF gene [6,7], basic ¢broblast growth factor
protein and other growth factors [21] and more recently,
transplantation of ex vivo expanded endothelial progenitor
cells [22]. In these clinical treatments, VEGF receptor-related
tyrosine kinase signaling may play a crucial role in the devel-
opment of new blood vessels. The present study suggests PTP
has an important role as the downstream inhibitor of VEGF
signaling and thus in angiogenic responses. Therefore, meth-
ods to prevent PTP’s functions may be useful in achieving
ideal therapeutic angiogenesis.
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